Direct-To-OTC Approvals, Line Extensions Replace Switches In 2000
This article was originally published in The Tan Sheet
Executive Summary
Direct-to-OTC drug introductions and line extensions dominated the list of new product rollouts in 2000. The year marked the first time since 1993 that no Rx-to-OTC switches were approved, although FDA reviewed several switch candidates.
You may also be interested in...
Dimetapp Line Extensions Filling Void Of PPA Product Withdrawals
Two new Whitehall-Robins' Dimetapp formulations are debuting at the height of the cough/cold season, replacing phenylpropanolamine-containing remedies withdrawn from the market in November.
Abreva Shortened Healing Time, Duration Of Cold Sores Stressed In Promos
SmithKline Beecham's Abreva, now hitting shelves in food, drug and mass outlets, is the first OTC indicated for shortening the healing time and duration of symptoms related to cold sores and fever blisters.
McNeil Children's Motrin Combination Suspension Creates New Category
McNeil Consumer Healthcare has received the go-ahead to launch the first ibuprofen/pseudoephedrine OTC pediatric product following FDA's approval of its NDA for Children's Motrin Cold Suspension Aug. 1.